Short description
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Description
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec.
The company was established in 2001 and is based in Cambridge, Massachusetts.
Last funding
Cannot Access
Sign in for full access
Total funding
$$3123123
Sign in for full access
Location
Cambridge, Massachusetts, United States, North America
Founded on
January 1, 2001
Exited on
March 12, 2010
Went public on
March 12, 2010
Stock symbol
AVEO
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$56378 - 90123
Sign in for full access
Investors
Absolutely Noaccess, Blurry Noaccess, No Way, Nopepepe, Noaccess, Noway Youcantaccess, Noaccessforu, Uh Ohhhh, Cannot Access, Uh Ohhhh, Noaccess, Noway Youcantaccess, Absolutely Noaccess, Noaccessforu
Sign in for full access
Founders
Kenneth E. Weg, Lynda Chin, Paul Hurley, Ronald A. DePinho